equin
coronaviru
ecov
consid
involv
enter
diseas
foal
recent
sever
outbreak
ecov
infect
also
report
adult
hors
usa
franc
japan
epidemiolog
studi
ecov
infect
still
limit
seropreval
ecov
infect
europ
unknown
studi
indirect
enzymelink
immunosorb
assay
elisa
method
util
ecov
spike
protein
develop
two
format
valid
analyz
pair
serum
sampl
acut
convalesc
sera
hors
involv
ecov
outbreak
sera
hors
unknown
ecov
exposur
format
show
high
diagnost
accuraci
compar
viru
neutral
vn
assay
receiveroper
characterist
roc
analys
perform
determin
best
cutoff
valu
elisa
format
assum
test
specif
employ
develop
elisa
method
detect
seroconvers
hors
ecov
outbreak
among
hors
sera
seroposit
vari
young
hors
adult
hors
dutch
hors
popul
sera
iceland
hors
includ
studi
signific
number
sera
found
posit
overal
result
demonstr
ecov
elisa
reliabl
diagnost
perform
compar
vn
assay
use
assay
support
seroconvers
hors
involv
ecov
outbreak
estim
ecov
seropreval
popul
hors
coronavirus
cov
envelop
posit
singlestrand
rna
virus
belong
subfamili
orthocoronavirina
famili
coronavirida
order
nidoviral
classifi
four
genera
alpha
beta
gammaand
deltacoronaviru
infect
mammalian
avian
host
equin
coronaviru
ecov
belong
betacoronaviru
speci
within
embecoviru
subgenu
betacoronaviru
genu
human
coronaviru
bovin
coronaviru
ecov
isol
first
time
twoweekold
diarrheic
foal
north
carolina
usa
suggest
role
ecov
caus
enter
diseas
sinc
sever
case
ecov
infect
also
report
adult
hors
unit
state
europ
japan
equin
coronaviru
detect
fecal
sampl
hors
clinic
sign
includ
anorexia
lethargi
fever
less
frequent
diarrhea
colic
neurolog
deficit
morbid
rate
vari
outbreak
mortal
low
relat
endotoxemia
septicemia
hyperammonemiaassoci
encephalopathi
outbreak
adult
hors
demand
studi
pathogenesi
epidemiolog
ecov
infect
diagnost
assay
high
sensit
specif
crucial
ecov
known
associ
enter
infect
also
detect
small
percentag
hors
respiratori
sign
viru
shed
observ
fecal
sampl
nasal
swab
sick
hors
well
healthi
hors
strong
associ
clinic
sign
assum
relat
ecov
infect
viru
detect
fecal
sampl
suggest
possibl
etiolog
role
ecov
recent
realtim
quantit
pcr
qpcr
method
establish
shown
abl
detect
ecov
fece
effici
howev
ecov
viral
nucleic
acid
gener
detect
qpcr
within
limit
timefram
day
post
infect
report
field
experiment
studi
hand
serolog
assay
use
support
diagnosi
clinic
ecov
infect
show
seroconvers
signific
increas
antibodi
titer
pair
serum
sampl
serolog
assay
also
need
gain
insight
transmiss
rate
infect
within
anim
popul
antibodi
induc
betacoronavirus
persist
blood
longer
period
infect
viru
neutral
vn
assay
long
use
gold
standard
confirm
serolog
respons
coronaviru
infect
although
vn
assay
highli
specif
detect
antibodi
also
timeconsum
labori
perform
altern
highthroughput
serolog
assay
correl
well
neutral
antibodi
therefor
need
sever
infect
ecov
shown
associ
high
viral
load
mild
asymptomat
infect
may
occur
low
level
viru
replic
neg
pcr
variabl
immun
respons
consequ
specif
sensit
highthroughput
serodiagnost
method
necessari
avoid
underestim
preval
surveil
studi
spike
protein
coronavirus
key
mediat
viru
cell
entri
therefor
major
target
neutral
antibodi
ectodomain
consist
two
function
interdepend
subunit
ntermin
subunit
respons
receptor
bind
ctermin
subunit
mediat
membran
fusion
subunit
variabl
immunogen
antigen
among
coronavirus
therefor
ideal
candid
detect
cov
speciesspecif
antibodi
object
studi
develop
valid
elisa
method
detect
specif
antibodi
ecov
provid
tool
diagnosi
futur
estim
ecov
preval
incid
variou
equin
sub
popul
total
equin
serum
sampl
includ
studi
detail
serum
panel
ah
n
shown
tabl
retriev
serum
bank
gd
anim
health
devent
netherland
collect
monitor
diseas
independ
studi
ecov
exposur
statu
unknown
except
panel
h
collect
iceland
serum
sampl
panel
g
collect
hors
netherland
addit
panel
includ
pair
acuteand
convalescentphas
serum
sampl
collect
ecov
outbreak
usa
sampl
store
c
test
ecov
strain
propag
titrat
human
rectal
adenocarcinoma
cell
cell
human
embryon
kidney
cell
stabli
express
larg
antigen
maintain
dulbecco
modifi
eagl
medium
dmem
lonza
basel
switzerland
sequenc
subunit
spike
protein
ecov
strain
residu
amino
acid
sequenc
deriv
genbank
genbank
human
codonoptim
sequenc
encod
ecov
subunit
synthes
fuse
fc
domain
mous
subsequ
clone
pcagg
mammalian
express
vector
describ
ecov
protein
product
express
plasmid
transfect
cell
use
polyethyleneimin
polysci
inc
warrington
pa
usa
ratio
h
incub
transfect
medium
remov
replac
sfm
ii
express
medium
gibco
life
technolog
inc
grand
island
ny
usa
six
day
post
transfect
cell
cultur
supernat
harvest
solubl
purifi
cultur
medium
use
protein
sepharos
bead
ge
healthcar
bioscienc
ab
uppsala
sweden
subsequ
protein
elut
use
citric
acid
ph
immedi
neutral
trishcl
ph
puriti
integr
protein
analyz
sodium
dodecyl
sulphat
polyacrylamid
gel
electrophoresi
sdspage
stain
gelcodeblu
stain
reagent
thermofish
scientif
inc
waltham
usa
purifi
protein
quantifi
nanodrop
spectrophotometri
thermofish
scientif
inc
waltham
usa
sodium
dodecyl
sulphat
polyacrylamid
gel
electrophoresi
sdspage
bovin
serum
albumin
bsa
standard
store
c
usag
equin
sera
n
randomli
select
differ
serum
panel
ad
test
neutral
antibodi
titer
ecov
vn
assay
heatinactiv
equin
sera
c
min
serial
dilut
dmem
supplement
fetal
bovin
serum
mix
equal
volum
ecov
strain
tissu
cultur
infect
dose
tcid
well
cell
cultur
plate
corn
inc
kennebunk
usa
virusserum
mixtur
incub
c
min
virusserum
mixtur
ad
duplic
cell
monolay
cell
cultur
plate
six
day
post
infect
clear
cytopath
effect
cpe
observ
viru
neutral
titer
vnt
determin
vnt
sera
express
reciproc
highest
serum
dilut
result
neutral
cpe
titer
consid
posit
two
differ
format
develop
employ
ecov
protein
socal
wet
format
elisa
welisa
dri
format
elisa
delisa
ecov
wet
format
elisa
welisa
highbind
microtit
plate
greiner
bioon
bv
alphen
aan
den
rijn
netherland
coat
ecov
protein
per
well
phosphat
buffer
salin
pb
ph
overnight
c
optim
protein
amount
dilut
secondari
antibodi
conjug
determin
checkerboard
titrat
protein
concentr
use
three
wash
pb
contain
pbst
plate
block
pbst
contain
milk
powder
protifar
nutricia
zoeterm
netherland
h
c
follow
block
plate
incub
serum
sampl
dilut
pbst
contain
milk
powder
h
c
wash
step
dilut
horseradish
peroxidas
hrp
conjug
goat
antihors
igg
h
l
abnova
taiwan
china
ad
detect
bound
antibodi
plate
incub
h
c
subsequ
plate
wash
peroxidas
reaction
visual
via
incub
plate
tmb
super
slow
one
compon
hrp
microwel
substrat
biofx
surmod
ivd
inc
eden
prairi
mn
usa
min
room
temperatur
reaction
stop
ad
sulfur
acid
h
vwr
intern
bv
amsterdam
netherland
optic
densiti
od
immedi
measur
nm
use
elisa
micropl
reader
biotek
instrument
inc
winooski
vt
usa
serum
sampl
test
duplic
ecov
dri
format
elisa
delisa
highbind
microtit
plate
greiner
bioon
bv
alphen
aan
den
rijn
netherland
coat
ecov
protein
per
well
ammoniumcarbon
solut
gl
vwr
intern
bv
amsterdam
netherland
overnight
c
block
solut
gl
ammoniumcarbon
gl
casein
vwr
intern
bv
amsterdam
netherland
gl
sucros
merck
co
inc
kenilworth
nj
usa
ad
plate
incub
one
hour
room
temperatur
subsequ
content
plate
discard
plate
dri
four
hour
c
vacuum
seal
store
c
optim
protein
amount
dilut
secondari
antibodi
conjug
determin
checkerboard
titrat
protein
concentr
use
plate
incub
serum
sampl
per
well
dilut
pb
dri
milk
biorad
laboratori
inc
hercul
ca
usa
h
c
wash
step
five
time
pbst
biotek
automat
wash
station
per
well
dilut
horseradish
peroxidas
hrp
conjug
goat
antihors
igg
h
l
abnova
taiwan
china
ad
detect
bound
antibodi
incub
h
c
subsequ
plate
wash
use
wash
procedur
peroxidas
reaction
visual
incub
plate
tmb
idexx
laboratori
westbrook
nj
usa
min
room
temperatur
reaction
stop
ad
sulfur
acid
h
vwr
intern
bv
amsterdam
netherland
optic
densiti
od
immedi
measur
nm
use
elisa
micropl
reader
biotek
instrument
inc
winooski
vt
usa
serum
sampl
test
duplic
sp
valu
calcul
formula
sp
od
sampleod
neg
control
od
posit
controlod
neg
control
correl
od
valu
score
two
elisa
format
measur
pearson
correl
coeffici
use
graph
pad
prism
version
discrimin
power
two
differ
elisa
format
analyz
perform
receiv
oper
characterist
roc
analysi
sera
neg
vnt
posit
vnt
cutoff
valu
diagnost
specif
sensit
determin
roc
analysi
use
sigmaplot
minimum
specif
chosen
select
cutoff
valu
addit
reproduc
assay
evalu
test
three
sampl
differ
od
valu
interassay
coeffici
variat
cv
intraassay
cv
determin
test
sampl
triplic
three
differ
plate
three
differ
run
within
plate
respect
identifi
equin
sera
contain
ecovneutr
antibodi
screen
subset
equin
sera
compos
randomli
select
serum
sampl
panel
ac
sampl
panel
screen
vn
assay
sera
sera
test
neg
titer
posit
sampl
titer
rang
addit
pair
sampl
hors
n
panel
test
vn
assay
twenti
sera
collect
first
time
point
exhibit
titer
rang
convalesc
serum
sampl
collect
day
follow
first
round
sampl
collect
show
neutral
respons
titer
rang
within
hors
seven
show
seroconvers
show
signific
greater
increas
titer
vn
assay
confirm
presenc
ecov
specif
igg
iceland
hors
hors
sera
posit
ecov
elisa
result
panel
h
sp
valu
test
ecov
neutral
assay
neutral
antibodi
titer
vari
besid
convent
wet
elisa
format
welisa
gener
laboratori
usag
dri
standard
elisa
format
delisa
also
develop
valid
facilit
implement
routin
diagnost
method
differ
laboratori
possibl
wider
applic
elisa
kit
elisa
format
develop
detect
ecovspecif
antibodi
hors
serum
sampl
diagnost
perform
elisa
evalu
use
subset
hors
sera
known
vn
result
describ
pearson
correl
coeffici
calcul
assess
correl
od
valu
obtain
two
elisa
format
figur
result
indic
od
valu
obtain
elisa
show
high
degre
correl
correl
regress
coeffici
close
r
regress
coeffici
p
thu
perform
elisa
format
similar
addit
pair
sampl
hors
n
panel
test
vn
assay
twenti
sera
collect
first
time
point
exhibit
titer
rang
convalesc
serum
sampl
collect
day
follow
first
round
sampl
collect
show
neutral
respons
titer
rang
within
hors
seven
show
seroconvers
show
signific
greater
increas
titer
vn
assay
confirm
presenc
ecov
specif
igg
iceland
hors
hors
sera
posit
ecov
elisa
result
panel
h
sp
valu
test
ecov
neutral
assay
neutral
antibodi
titer
vari
besid
convent
wet
elisa
format
welisa
gener
laboratori
usag
dri
standard
elisa
format
delisa
also
develop
valid
facilit
implement
routin
diagnost
method
differ
laboratori
possibl
wider
applic
elisa
kit
elisa
format
develop
detect
ecovspecif
antibodi
hors
serum
sampl
diagnost
perform
elisa
evalu
use
subset
hors
sera
known
vn
result
describ
pearson
correl
coeffici
calcul
assess
correl
od
valu
obtain
two
elisa
format
figur
result
indic
od
valu
obtain
elisa
show
high
degre
correl
correl
regress
coeffici
close
r
regress
coeffici
p
thu
perform
elisa
format
similar
subsequ
discrimin
power
welisa
delisa
evalu
via
receiv
oper
characterist
roc
analysi
roc
curv
plot
base
previou
classif
sera
neg
posit
vn
assay
figur
b
optim
cutoff
valu
diagnost
specif
sensit
elisa
format
determin
establish
roc
curv
elisa
result
vntposit
neg
sampl
shown
figur
diagnost
accuraci
elisa
format
consid
high
area
curv
auc
valu
observ
auc
rel
sensit
specif
approxim
accord
youden
plot
welisa
delisa
therefor
test
characterist
elisa
format
assign
weight
studi
minimum
specif
chosen
threshold
cutoff
valu
elisa
accordingli
optim
cutoff
welisa
od
valu
sensit
specif
delisa
test
result
express
sp
valu
cutoff
sp
valu
yield
sensit
specif
respect
subsequ
discrimin
power
welisa
delisa
evalu
via
receiv
oper
characterist
roc
analysi
roc
curv
plot
base
previou
classif
sera
neg
posit
vn
assay
figur
b
optim
cutoff
valu
diagnost
specif
sensit
elisa
format
determin
establish
roc
curv
elisa
result
vntposit
neg
sampl
shown
figur
diagnost
accuraci
elisa
format
consid
high
area
curv
auc
valu
observ
auc
rel
sensit
specif
approxim
accord
youden
plot
welisa
delisa
therefor
test
characterist
elisa
format
assign
weight
studi
minimum
specif
chosen
threshold
cutoff
valu
elisa
accordingli
optim
cutoff
welisa
od
valu
sensit
specif
delisa
test
result
express
sp
valu
cutoff
sp
valu
yield
sensit
specif
respect
furthermor
interand
intracoeffici
variat
cv
three
ecov
posit
sera
test
elisa
format
lower
specif
intraassay
cv
welisa
delisa
rang
respect
interassay
cv
welisa
delisa
vari
respect
overal
result
indic
perform
elisa
format
much
equival
result
elisa
strongli
correl
vn
result
determin
diagnost
perform
ecov
elisa
pair
serum
sampl
panel
collect
acut
ecov
outbreak
investig
welisa
hors
present
similar
clinic
sign
describ
viru
shed
confirm
qpcr
analysi
acut
stage
hors
qpcr
posit
convalesc
stage
number
decreas
six
serum
sampl
valid
vn
assay
figur
tabl
seven
hors
show
seroconvers
anoth
hors
show
signific
greater
increas
vnt
perform
welisa
see
figur
tabl
seven
hors
show
seroconvers
acut
phase
sera
neg
od
valu
wherea
convalesc
phase
sera
od
valu
greater
thu
seroconvers
rate
calcul
welisa
vnt
show
correl
tabl
hors
show
greater
increas
vnt
n
nine
acut
phase
sera
posit
od
valu
background
also
higher
n
n
fold
increas
od
valu
convalesc
serum
five
vnt
posit
pair
serum
sampl
od
valu
twice
background
od
valu
acut
phase
serum
two
sampl
od
valu
respect
welisa
also
show
greater
increas
od
valu
three
vnt
posit
sampl
less
increas
od
valu
alreadi
high
furthermor
interand
intracoeffici
variat
cv
three
ecov
posit
sera
test
elisa
format
lower
specif
intraassay
cv
welisa
delisa
rang
respect
interassay
cv
welisa
delisa
vari
respect
overal
result
indic
perform
elisa
format
much
equival
result
elisa
strongli
correl
vn
result
determin
diagnost
perform
ecov
elisa
pair
serum
sampl
panel
collect
acut
ecov
outbreak
investig
welisa
hors
present
similar
clinic
sign
describ
viru
shed
confirm
qpcr
analysi
acut
stage
hors
qpcr
posit
convalesc
stage
number
decreas
six
serum
sampl
valid
vn
assay
figur
tabl
seven
hors
show
seroconvers
anoth
hors
show
signific
greater
increas
vnt
perform
welisa
see
figur
tabl
seven
hors
show
seroconvers
acut
phase
sera
neg
od
valu
wherea
convalesc
phase
sera
od
valu
greater
thu
seroconvers
rate
calcul
welisa
vnt
show
correl
tabl
hors
show
greater
increas
vnt
n
nine
acut
phase
sera
posit
od
valu
background
also
higher
n
n
fold
increas
od
valu
convalesc
serum
five
vnt
posit
pair
serum
sampl
od
valu
twice
background
od
valu
acut
phase
serum
two
sampl
od
valu
respect
welisa
also
show
greater
increas
od
valu
three
vnt
posit
sampl
less
increas
od
valu
alreadi
high
od
valu
acut
phase
serum
well
high
vnt
mean
od
valu
mean
vnt
six
hors
show
signific
rise
vnt
five
serum
sampl
collect
acut
stage
alreadi
high
antibodi
level
shown
elisa
neutral
assay
mean
od
valu
mean
vnt
tabl
pearson
correl
coeffici
calcul
assess
overal
correl
od
valu
obtain
welisa
vnt
titer
acut
convalescentphas
sera
hors
figur
result
indic
od
valu
vnt
show
good
degre
correl
r
p
data
support
use
welisa
diagnost
tool
case
suspect
ecov
outbreak
od
valu
acut
phase
serum
well
high
vnt
mean
od
valu
mean
vnt
six
hors
show
signific
rise
vnt
five
serum
sampl
collect
acut
stage
alreadi
high
antibodi
level
shown
elisa
neutral
assay
mean
od
valu
mean
vnt
tabl
pearson
correl
coeffici
calcul
assess
overal
correl
od
valu
obtain
welisa
vnt
titer
acut
convalescentphas
sera
hors
figur
result
indic
od
valu
vnt
show
good
degre
correl
r
p
data
support
use
welisa
diagnost
tool
case
suspect
ecov
outbreak
set
determin
seropreval
hors
unknown
ecov
exposur
use
delisa
format
total
serum
sampl
tabl
panel
ah
analyz
except
panel
sera
adult
hors
older
month
seropreval
vari
panel
panel
c
among
eight
serum
panel
lowest
number
posit
sampl
found
panel
contain
young
hors
month
old
averag
age
month
ci
four
serum
panel
panel
b
e
f
dutch
hors
histor
serum
sampl
panel
g
sampl
iceland
panel
h
higher
seropreval
found
tabl
preval
ecov
antibodi
equin
sera
use
studi
set
determin
seropreval
hors
unknown
ecov
exposur
use
delisa
format
total
serum
sampl
tabl
sinc
begin
centuri
ecov
infect
report
hors
caus
fever
enter
diseas
recent
infect
adult
hors
report
clinic
sign
fever
anorexia
lethargi
less
commonli
specif
sign
diarrhea
colic
nevertheless
inform
regard
circul
ecov
equin
popul
especi
europ
still
limit
serolog
studi
use
tool
investig
ecov
preval
hors
popul
present
studi
aim
develop
simpl
reliabl
method
antibodi
detect
ecov
use
diagnost
seroepidemiolog
studi
compar
viru
neutral
assay
elisa
method
advantag
reproduc
potenti
highthroughput
much
less
labori
studi
set
ecov
elisa
method
two
complementari
format
convent
welisa
format
gener
laboratori
usag
simplifi
easi
perform
coat
procedur
hand
coat
plate
delisa
format
could
store
longer
time
period
make
ideal
transport
kit
develop
show
format
perform
equal
well
result
correl
nice
compar
vn
assay
roc
analysi
elisa
method
format
shown
high
accuraci
current
studi
appli
welisa
analysi
pair
outbreak
sampl
delisa
valid
use
highthroughput
screen
larger
amount
serum
sampl
util
ecov
viral
antigen
antibodi
detect
studi
chimer
protein
express
mammalian
cell
henc
protein
conform
modif
eg
glycosyl
mimick
protein
surfac
viru
particl
diverg
immunodomin
compon
coronavirus
wide
use
develop
method
specif
coronaviru
serolog
studi
find
valid
ecov
highli
suitabl
antigen
detect
antibodi
ecov
show
good
agreement
elisa
vn
assay
recent
similar
conclus
also
drawn
role
mer
mer
serolog
welisa
method
abl
analyz
pair
sampl
collect
ecov
outbreak
viru
neutral
assay
seroconvers
greater
increas
ecov
antibodi
titer
could
detect
sera
hors
within
week
initi
observ
clinic
diseas
detect
viral
rna
fece
posit
hors
show
seroconvers
higher
increas
od
valu
welisa
three
remain
vnt
posit
sampl
high
od
valu
alreadi
acut
phase
serum
six
ecov
neg
pair
sampl
five
high
vn
antibodi
titer
od
valu
alreadi
acut
phase
might
due
late
sampl
hors
previou
exposur
ecov
tabl
studi
confirm
ecov
elisa
use
diagnost
test
demonstr
potenti
ecov
outbreak
consid
use
adjunct
investig
fecal
sampl
qpcr
also
determin
seropreval
serum
sampl
collect
hors
unknown
ecov
exposur
via
delisa
result
show
overal
seropreval
differ
cohort
test
percentag
agreement
studi
perform
hemida
et
al
detect
coronaviru
infect
hors
saudi
arabia
oman
found
detect
neutral
antibodi
ecov
lower
percentag
posit
anim
found
anoth
ecov
seropreval
studi
conduct
usa
sever
factor
might
contribut
differ
result
limit
inform
regard
ecov
preval
europ
includ
netherland
possibl
overal
ecov
distribut
differ
contin
moreov
studi
employ
eukaryot
express
ecov
protein
coat
antigen
us
studi
chimer
protein
express
escherichia
coli
use
express
mammalian
cell
guarante
nativ
configur
protein
particular
glycosyl
antigen
coronaviru
spike
protein
report
shown
coronaviru
subunit
elicit
antibodi
respons
level
immun
respons
trigger
may
differ
furthermor
criteria
determin
cutoff
valu
differ
two
studi
studi
defin
posit
neg
sampl
basi
vn
assay
wherea
us
studi
use
neg
qrtpcr
absenc
clinic
sign
criteria
defin
hors
ecov
neg
way
seroposit
hors
may
contribut
higher
cutoff
valu
potenti
lower
sensit
assay
studi
notic
differ
seropreval
young
adult
hors
group
young
hors
panel
tabl
lowest
seropreval
found
young
hors
may
initi
protect
ecov
infect
matern
antibodi
may
becom
gradual
suscept
matern
antibodi
wane
risk
becom
infect
increas
age
hypothesi
support
age
distribut
pcrconfirm
ecov
infect
case
foal
age
month
lowest
infect
rate
infect
rate
increas
age
also
observ
signific
percentag
seroposit
hors
serum
sampl
collect
back
panel
g
tabl
ecovlik
virus
detect
electron
microscopi
fece
hors
enter
diseas
viru
isol
character
report
histori
ecov
presenc
especi
europ
possibl
much
longer
current
understood
intriguingli
notic
iceland
hors
also
seroposit
ecov
panel
h
tabl
twentyfour
serum
sampl
show
high
ecov
elisa
reactiv
sp
valu
also
neutral
antibodi
vnt
vari
hors
popul
iceland
geograph
isol
year
free
common
equin
contagi
diseas
equin
influenza
equin
herpesviru
strangl
equin
viral
arter
date
prior
studi
ecov
preval
hors
iceland
perform
first
evid
exist
ecov
infect
iceland
conclus
develop
highthroughput
reliabl
specif
elisa
method
studi
humor
immun
respons
hors
ecov
method
abl
perform
serodiagnosi
ecov
infect
assess
seropreval
within
hors
popul
futur
supplementari
materi
follow
avail
onlin
http
tabl
detect
antibodi
ecov
equin
serum
sampl
ecov
outbreak
welisa
winter
figur
correl
od
valu
obtain
welisa
viru
neutral
titer
vnt
hors
acut
convalescentphas
sera
